Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program

Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real‐life cohort of 16,703 cons...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2019-12, Vol.145 (12), p.3359-3369
Hauptverfasser:	Jacot, William, Heudel, Pierre‐Etienne, Fraisse, Julien, Gourgou, Sophie, Guiu, Séverine, Dalenc, Florence, Pistilli, Barbara, Campone, Mario, Levy, Christelle, Debled, Marc, Leheurteur, Marianne, Chaix, Marie, Lefeuvre, Claudia, Goncalves, Anthony, Uwer, Lionel, Ferrero, Jean‐Marc, Eymard, Jean‐Christophe, Petit, Thierry, Mouret‐Reynier, Marie‐Ange, Courtinard, Coralie, Cottu, Paul, Robain, Mathieu, Mailliez, Audrey
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer Chemotherapy Clinical trials Disease-Free Survival ErbB-2 protein eribulin Female Furans - therapeutic use Humans Ketones - therapeutic use Life Sciences Medical research Metastases Metastasis metastatic breast cancer Middle Aged Progression-Free Survival real‐life cohort Receptor, ErbB-2 - metabolism Retrospective Studies Survival Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!